This cross-sectional, non-interventional survey study (n=1000) aims to investigate the effects of psychedelic experiences on fundamental beliefs and mental health in individuals who have used psychedelic substances.
This study is recruiting participants to explore the relationship between beliefs about free will and determinism, depression, and the use of psychedelics. Conducted by Charité Universitätsmedizin Berlin, Germany, under the lead of Dr. med. Michael Koslowski, the study is open to participants aged 18 years and above with experience in psychedelic drug use and sufficient English language skills.
The primary outcome focuses on assessing links between beliefs about free will, psychedelic experiences, and depression, while secondary outcomes include factors such as life satisfaction and meaning in life. Data collection involves an anonymous survey study conducted in English, with endpoints including various questionnaires and assessments related to beliefs, mental health, and psychedelic experiences. The study, planned to start on April 22, 2024, is expected to recruit 1000 participants and aims to publish its results in January 2025.
Trial Details
Psychedelics are currently experiencing a renaissance in science. However, how they work exactly and what potential they offer for therapy is not yet clear. It is well established that psychedelic substances ("classical" / serotonergic psychedelics) such as LSD, psilocybin ("magic mushrooms"), DMT, ayahuasca or mescaline induce altered states of consciousness, which can lead to profound, sometimes even life-changing, experiences. This can lead to changes in our deeply rooted belief systems, which in turn might influence our mental health conditions. With this study, we aim to investigate the effects of psychedelic experiences on fundamental beliefs and mental health.NCT Number DRKS00034097
Sponsors & Collaborators
Charité – Universitätsmedizin BerlinThe MIND Foundation recently announced a partnership with Charité – Universitätsmedizin Berlin.